New Ray Medicine International Holding Company Description

New Ray Medicine International Holding Limited, an investment holding company, engages in distribution and trading of pharmaceutical and related products in the People’s Republic of China.

The company’s pharmaceutical products include levocarnitine injection for the treatment of muscular dystrophy, cardiomyopathy, acute and chronic myocardial infraction, angina pectoris, and parenteral nutrition; thoymosin α1 for injection to treat hepatitis and impaired immunity, HBe antiogen-positive, decompensated liver cirrhosis, severe hepatitis, tumor relating hepatitis B, and chronic hepatitis C; and cefamandole nafate, ceftizoxime sodium, and isepamicin sulfate injection for the treatment of respiratory tract infections, genitourinary system infections, urinary tract infections, intra-abdominal infections, bone, joint infections, and septicemia.

It also provides alanyl glutamine for injection that is indicated for catabolism and hypermetabolism; cefixime dispersible tablets to treat infections caused by streptococcus and pneumococcus, chronic bronchitis, acute bronchitis with bacterial infection, pneumonia, pyelonephritis, cystitis, gonococcal urethritis, and acute bacterial infection of the biliary tract system; and clostridium butyricum capsule for diarrhea and digestive system relevant illness.

Further, the company offers marketing and promotion services. The company was founded in 2001 and is headquartered in Hangzhou, the People’s Republic of China.

New Ray Medicine International Holding Limited

Country	Bermuda
Founded	2001
Industry	Drugs, Drug Proprietaries, and Druggists' Sundries
Employees	29
CEO	Qiuqin Wang

Contact Details

Address: Dikai International Center Hangzhou China
Website	newraymedicine.com

Stock Details

Ticker Symbol	2908
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	HKD
SIC Code	5122

Key Executives

Name	Position
Qiuqin Wang	Chief Executive Officer
Yat Sing Ng	Chief Financial Officer